10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy

Vaccine

Volumn 22, Issue 27-28, 2004, Pages 3649-3657

  Katoch, Kiran ^a   Katoch, Vishwa Mohan ^a   Natrajan, Mohan ^a   Sreevatsa, ^a   Gupta, Umesh Dutt ^a   Sharma, Vishnu Dutt ^a   Shivanavar, Channappa T ^a  

^a NATIONAL JALMA INSTITUTE FOR LEPROSY AND OTHER MYCOBACTERIAL DISEASES   (India)

Author keywords

Chemotherapy; Immunotherapy; Leprosy; Long term follow up

Indexed keywords

BCG VACCINE; CORTICOSTEROID; DAPSONE; RIFAMPICIN; STEROID; WATER;

ADOLESCENT; ADULT; ARTICLE; BACILLUS; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; GRANULOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; LEPROSY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SIDE EFFECT; SMEAR; TIME SERIES ANALYSIS; WORLD HEALTH ORGANIZATION;

ADENOSINE TRIPHOSPHATE; ADOLESCENT; ADULT; ANIMALS; BCG VACCINE; BIOLOGICAL ASSAY; CLOFAZIMINE; COMBINED MODALITY THERAPY; DAPSONE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FOOT; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOTHERAPY; LEPROSTATIC AGENTS; LEPROSY, LEPROMATOUS; MALE; MICE; MIDDLE AGED; RIFAMPIN; VACCINATION;

EID: 4143132183     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.03.037     Document Type: Article

References (32)

1. WHO Expert Committee on Leprosy. Sixth Report. WHO Tech Rep Ser 768. Geneva: World Health Organization; 1988.
2. World Health Organization. Progress towards elimination of leprosy as a public health problem, Weekly Epidemiol Rec 1993; 68: 181-88.
3. WHO Expert Committee on Leprosy. Seventh report. WHO Tech Rep Ser No 874. Geneva: World Health Organization; 1998.
4. Jamet P., Ji B., Blanc L. The Marchoux Chemotherapy Study Group Relapse rate after long term follow up of multibacillary patients treated by WHO multidrug regimen. Int. J. Lepr. 63:1995;195-201
5. Grosset J. Recent developments in the field of multidrug therapy and future research in chemotherapy of leprosy. Lepr. Rev. 57:1986;223-234
6. Iyer C.G.S., Balakrishnan S., Ramu G. A comparison of low and conventional dosage of Dapsone in treatment of lepromatous leprosy. Lepr. India. 49:1977;372-386
7. Desikan K.V., Venkitaramanaiah H.N. A modified method of harvesting M. leprae from the foot pads of mice. Lepr. India. 48:1976;157-162
8. Katoch V.M., Katoch K., Ramanathan U., et al. Effect of chemotherapy on viability of Mycobacterium leprae as determined by ATP content, morphological Index, and FDA-EB staining. Int. J. Lepr. 57:1989;615-631
9. Katoch K., Ramu G., Ramanathan U., et al. Results of a modified WHO regimen in highly bacilliferous BL/LL patients. Int. J. Lepr. 57:1989;451-457
10. Katoch K., Katoch V.M., Natrajan M., et al. Treatment of bacilliferrous BL/LL cases with combined chemotherapy and immunotherapy. Int. J. Lepr. 63:1995;202-212
11. Natrajan M., Katoch K., Bagga A.K., Katoch V.M. Histological changes in combined chemotherapy and immunotherapy in highly bacillated lepromatous leprosy. Acta Leprol. 8(2):1992;79-86
12. Stanford J.L., Rook G.A.W., Bahr G.M., et al. Mycobacterium vaccae in the immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Vaccine. 8:1990;525-530
13. Zaheer S.A., Mukherjee R., Beena K.R., et al. Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy. J. Infect. Dis. 167:1993;401-410
14. Convit J., Pinardi M.E., Rodriguez O.G. Elimination of Mycobacterium leprae by other mycobacteria. Clin. Exp. Immunol. 17:1974;821-826
15. Sharma P., Mishra R.S., Kar H.K., et al. Mycobacterium w vaccine, a useful adjuvant to multidrug therapy in multibacillary leprosy a report on hospital-based immunotherapeutic clinical trials with a follow-up of 1-7 years after treatment. Lepr. Rev. 71(1):2000;179-192
16. Sarkar ADe., Kaur I., Radotra B.D., Kumar B. Impact of combined mycobacterium w vaccine and 1 year of MDT on multibacillary leprosy patients. Int. J. Lepr. 60(3):2001;187-194
17. Kar H.K., Sharma A.K., Mishra R.S., et al. Reversal reactions in multibacillary leprosy patients following MDT with and without immunotherapy with a candidate anti-leprosy vaccine Mycobacterium w. Lepr. Rev. 64:1993;219-226
18. Bhatki W.S., Chulawala R.G. The immunotherapeutic potential of ICRC vaccine - a case-controlled study. Lepr. Rev. 63:1992;358-364
19. Kaplan G., Britton W.J., Hancock G.E., et al. The systemic effect of recombinant interleukin-2 on the manifestations of lepromatous leprosy. J. Exp. Med. 173:1991;993-1006
20. Fernandez JMM. Use of BCG in immunoprophylaxis of leprosy. Rev Arg Dermatol 1939;23:425.
21. Convit J., Aranzazu N., Ulrich M. Immunotherapy with a mixture of Mycobacterium leprae and BCG in different forms of leprosy and in Mitsuda negative contacts. Int. J. Lepr. 50:1982;415-424
22. Meyer W.M., McDougall A.C., Flurry R.N., et al. Histological responses in sixty multibacillary leprosy patients inoculated with autoclaved Mycobacterium leprae and live BCG. Int. J. Lepr. 56:1988;302-309
23. Katoch K., Natarajan M., Narayanan R.B., Katoch V.M. Immunotherapy of treated BL/LL cases with BCG: histological, immunohistological and bacteriological assessment. Acta Leprol. 7(1):1989;153-155
24. Mukherjee A., Zaheer S.A., Sharma A.K., et al. Histopathological monitoring of an immunotherapeutic trial with Mycobacterium w. Int. J. Lepr. 60:1992;28-34
25. Hasting RC, Job CK. Reversal reaction in lepromatous leprosy following transfer factor therapy. Am J Trop Med Hyg 1978;27:995-1004.
26. Kaplan G., Britton W.J., Hancock J.E., et al. The systemic effect of recombinant interleukin-2 on the manifestations of lepromatous leprosy. J. Exp. Med. 173:1991;993-1006
27. Mathur N.K., Mittal A., Mathur D., Jain S.K. Long term follow-up of lepromatous leprosy patients receiving intralesional recombinant gamma interferon. Int. J. Lepr. 60:1992;98-100
28. Subcommittee on clinical trials of scientific working group on chemotherapy of leprosy (THELEP) of UNDP/World Bank/WHO special programme for research in tropical diseases. THELEP controlled clinical drug trials, Int J Lepr 1987; 55 (Suppl): 864-68.
29. Sreevatsa, Girdhar BK, Desikan KV, Screening of drug resistant strains of Mycobacterium lepraein lepromatous leprosy patients under moltidrug therapy, Indian J Med Res 1988; 87: 139-143.
30. Becx-Bleumink M. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy programme of the All Africa Leprosy and Rehabilitation Training Centre (ALERT), Ethopia. Int. J. Lepr. 60:1992;161-172
31. WHO leprosy unit. Risk of relapse in leprosy. WHO document. WHO/CTD/Lep/94.1.
32. Marchoux Chemotherapy Study Group. Relapse rates in multibacillary leprosy patients after stopping treatment with Rifampicin containing combined regimens, Int J Lepr 1992; 60: 525-35.